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IntroductIon
The Neglected Tropical Diseases (NTDs) are a group of 17 pathologies, recognized by the World Health 
Organization (WHO), which are endemic in 149 countries of tropical and sub-tropical areas of the globe, 
and affect more than one billion people overall (Feasey et al. 2010). The pathologies are all caused by 
microparasites or macroparasites. Among the diseases provoked by microparasites, three are caused by 
kinetoplastidae, a group of flagellated protozoa transmitted by insect vectors: Chagas disease, Human 
African Trypanosomiasis and leishmaniasis. The focus of the present chapter is on the identification of new 
drugs for the treatment of trypanosomatidic infections such as Chagas disease, caused by Trypanosoma 
cruzi, and Human African Trypanosomiasis, caused by Trypanosoma brucei (Filardy et al. 2018). 
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chagas disease
Chagas disease, also referred to as American Trypanosomiasis, represents a serious medical and 
socioeconomic burden for over 21 regions of Latin America. More than 8 million people worldwide 
are estimated to be infected by T. cruzi and more than 10,000 deaths per year are reported. Recently, a 
reduction in incidence and prevalence of the infection has been observed, but on the other hand, a spread 
of the disease to previously unaffected regions as a consequence of massive migration fluxes, congenital 
transmission, and blood and organ donations has been reported, making Chagas disease a world health 
issue (Figure 1) (Pérez-Molina and Molina 2018).
The disease usually evolves from an acute to a chronic phase. The acute phase arises just after the 
infection and can last from a few weeks to several months and is characterized by non-specific symptoms 
(i.e., fever, swelling of skin and mucosa). Thereafter, the disease enters an asymptomatic chronic stage and 
only 20–30% of the infected people manifest lethal complications after several years (Bern et al. 2011). 
The treatment of both the acute and chronic stages of Chagas disease is based on chemotherapy. For almost 
50 years, benznidazol and nifurtimox (Figure 2) were the two first-line drugs for the treatment of Chagas 
disease (Rodriques Coura and de Castro 2002). Unfortunately, their efficacy is limited, and more frequently 
the side effects that the two drugs elicit during the treatment of the chronic stage induce the patients to 
quit the therapy. Nifurtimox treatment is discontinued in up to 75% of all cases, and benznidazol, which 
is better tolerated, is discontinued in 9 to 29% of the cases. Besides chemotherapy, serological cure is 
recommended for acute congenital Chagas during the first year of life, and for chronically infected children 
under 14 years (Pérez-Molina and Molina 2018). 
Human African trypanosomiasis (HAt)
Human African Trypanosomiasis (HAT), also known as sleeping sickness, is caused by the bloodstream 
form of the two protozoan parasites Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense 
(Büscher et al. 2017). The sleeping sickness is mainly spread in the poorest rural area of sub-Saharan Africa, 
Figure 1. Incidence of T. cruzi infection, based on official estimates and status of vector transmission. Adapted from WHO 2010.
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where the habitat is suitable for the survival of the tsetse fly, the vector responsible for the transmission 
of the parasite. In particular, T. b. gambiense is widespread in Central and Western Africa and causes 
over 98% of chronic HAT, whereas T. b. rhodensiense only infects humans occasionally and is mainly 
spread in Southern and Eastern Africa (Figure 3). Starting from 2009, and for the first time in thirty years, 
mostly due to WHO launched programs of surveillance and treatment, less than 10.000 new cases per year 
of HAT were registered in 2009. This represents a drop of 76% with respect to the 300,000 cases observed 
in 1995. This trend suggests that a complete eradication of HAT by 2020 is possible (WHO 2017). However, 
the number of cases registered by the WHO covers only the visible part of HAT incidence, whereas 
around 70 million people living in sub-Saharan Africa are exposed to T. brucei infection (Simarro et al. 
2012).
HAT can occur in an acute or chronic form. The acute form of the disease appears within few weeks 
of the initial injection of the trypomastigote form of the parasite into the host by the tsetse fly. It is 
characterized by non-specific flu-like symptoms including fever, headache and joint pain. Thereafter, similar 
to Chagas disease, the infection can remain quiescent for a long time period and re-emerge several years 
later (chronic form). The second stage starts when the parasite migrates across the blood-brain barrier into 
the central nervous system, resulting in neurological symptoms such as confusion, depleted coordination, 
sensory disturbances and disruption of the normal sleeping cycle (from which the name sleeping sickness 
was derived). Ultimately, progressive mental deterioration leads to coma and death (Kennedy 2013). 
Beside T. b. gambiense and rhodesiense, pathogens for humans, other Trypanosoma species (e.g., T. vivax, 
T. congolense and T. brucei evansi) are etiological agents of a variety of wasting diseases affecting domestic 
livestock, which collectively go by the name of Animal African Trypanosomiasis (AAT or Nagana). 
Nagana causes significant damage to cattle farming with 3 million heads lost each year, contributing to 
significant economical damage in countries with already fragile economic structures. Moreover, animals 
represent a reservoir for these parasites from which humans may be exposed to infection (Njiokou et al. 
2010). Therefore, fighting both HAT and AAT in the one health approach (Okello et al. 2014) is the only 
way to the complete eradication of this pathology (Giordani et al. 2016). The treatment of HAT, diversified 
Figure 2. Drugs currently in use for the treatment of Chagas disease and Human African Trypanosomiasis.
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depending on the stage of infection, is only based on chemotherapy (Cullen and Mocerino 2017). Nowadays, 
only four drugs and one drug combination are employed in therapy (Figure 2). Pentamidine is currently 
the first-line option for treating the initial stage of HAT (Sands et al. 1985) whereas suramin is employed 
as second choice or for the primary treatment of T. b. rhodesiense infection, for which it is more effective 
than pentamidine. However, both drugs suffer from important limitations: they are administered via 
injection, require a healthcare professional, are ineffective in stage two and, more importantly, have adverse 
side effects that are often responsible for the suspension of the treatment. Melarsoprol, eflornithine and 
nifurtimox, instead, are the only drugs actually effective in the second stage of HAT (Eperon et al. 2014). 
Melarsoprol was the first drug to be developed for HAT; it has been medically used since 1949 and it has 
the great advantage of being effective against both T. b. gambiense and rhodesiense infections. However, 
it derives from arsenic which is the reason for its undesirable effects, including fatal encephalopathy 
(Fairlamb et al. 2018). 
Eflornithine is the only recent drug approved for HAT in 2000. It is a less toxic alternative to 
melarsoprol, even though it is completely ineffective against T. b. rhodesiense. The main drawback of 
eflornithine is the complex regimen of intravenous infusions 4-times per day for 14 days of treatment 
(Chappuis et al. 2005). Today eflornithine is rarely used alone and is normally prescribed in combination 
with nifurtimox. Nifurtimox alone is less effective against T. brucei than T. cruzi, but in combination with 
eflornithine, the efficacy of the treatment is comparable to that of eflornithine alone, but with considerably 
fewer side-effects than the monotherapy. In addition, the regimen of eflornithine in combination with 
nifurtimox is more manageable, furthermore permitting an oral administration of the two drugs (Priotto 
et al. 2009). 
HAt and chagas diseases’ Social Impact and Intervention
Although one seventh of the world’s population has an interest in or is exposed to the risk of NTDs, 
these pathologies remain neglected at several levels. At the local level, they are usually not mentioned by 
Figure 3. Distribution of Human African Trypanosomiasis (T. b. gambiense in green and T. b. rhodesiense in blue) worldwide. 
Adapted from WHO 2017.
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affected people, who are afraid of bias and marginalisation by the community. These pathologies barely 
spread outside the tropical area of origin; they do not represent an immediate risk for the ‘occidental’ 
countries that tend to be disinterested. However, the price to be paid for these choices is high: the NTDs 
have an elevated impact on the life of every single person, family and community, drastically decreasing 
the quality of life, aggravating poverty and reducing productivity - therefore representing a barrier for the 
economic growth of already depleted countries (Weiss 2008). Notwithstanding the social and economic 
burden, research and development for these illnesses is limited. For example, among all the 1,393 new 
drugs approved between 1975 and 1999, only 13 (0.9%) were targeted for NTDs, and only four of those 
were developed by pharmaceutical companies. The other nine were discovered as a result of veterinary and 
military research (Trouiller et al. 2002). Therefore, in order to encourage the research and development 
of new drugs that could be more effective, safe and economically sustainable, and to overcome the lack 
of interest of the major pharmaceutical companies in this health issue, associations between public and 
private institutions (PPP, public-private partnership) were recently initiated (Liese et al. 2010). These 
include the European Commission (Pierce et al. 2017) and other government agencies, private foundations 
and pharmaceutical multinationals such as the Drugs for Neglected Diseases Initiative (DNDi) (Chatelain 
and Ioset 2011) and the Medicines for Malaria Venture (MMV 2018). These PPPs coordinate the basic 
research conducted by universities and public health organizations with the experience and technology 
of the chemical and technological pharmaceutical industries to develop new drug candidates. The DNDi, 
along with partners including the Bill & Melinda Gates Foundation (WA, USA), Sanofi (Paris, France) 
and Médecins Sans Frontières (Geneva, Switzerland) are attempting to address the deficiency in accessible 
treatments and currently have two oral candidates in clinical trials. Acoziborole (SCYX-7158) emerged 
as a safe and promising candidate in late 2009 for the treatment of the second stage of HAT (Eperon et al. 
2014). After successful preclinical trials, the drug entered clinical development in 2012, becoming a new 
chemical entity discovered by DNDi’s lead-optimization program. In 2016, acoziborole entered into a Phase 
II/III clinical trial, which is expected to be completed by April 2020 (Jacobs et al. 2011). Fexinidazole, 
discovered by DNDi in 2005, is currently the most advanced oral drug candidate being developed for first 
stage and early second stage HAT (Eperon et al. 2014). A pivotal Phase II/III trial was completed in 2016, 
although two additional ‘plug-in’ trials are currently ongoing to assess the efficacy of the drug in special 
population groups not examined in the initial cohort. In addition, DNDi is also running a Phase III trial 
examining the effectiveness of fexinidazole in patients treated on both an out-patient basis and in a clinical 
hospital setting—depending on status. These trials are going to be completed by March 2020 (Mesu et al. 
2018). Besides acoziborole and fexinidazole, which are two successful examples of new chemical entities 
identified for the treatment of trypanosomatidic infections, new drug candidates continuously enter the 
drug discovery pipeline.
drug discovery Approaches
Usually, the drug discovery for NTDs is carried out using classical ligand-based approaches, target-based 
approaches and phenotypic screening. Ligand-based approaches, which are discussed later in the chapter, 
are typically focused on the implementation of already known active compounds, natural compounds or 
drugs in therapy. Chemical structure modifications are then applied on the basis of classical medicinal 
chemistry strategies (Wermuth et al. 2015). Target-based approaches involve screening a library of 
compounds against a protein target and then optimizing the compounds for potency against the enzyme, 
selectivity, cellular activity, and pharmacokinetic properties. However, there are relatively few validated 
drug targets across the trypanosomiatidic infections (Frearson et al. 2007). Targets of major interest in 
the field of drug discovery are reported in Gilbert et al. (2013) and, in this chapter, we describe the main 
achievements in the fields of ergosterol biosynthesis, folate metabolism, phosphodiesterases, cysteine 
proteases and trypanothione metabolism. On the other hand, phenotypic screening has the advantage of 
identifying compounds that are active against the whole cell, meaning issues such as cell uptake and cell 
efflux have already been addressed (Haasen et al. 2017). There has been a major emphasis on phenotypic 
approaches to drug discovery for neglected diseases and a number of notable successes have been reported, 
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like the above mentioned fexinidazole and acoziborole (Eperon et al. 2014). Nonetheless, a balanced 
portfolio of carefully selected ligand- and target-based approaches together with phenotypic approaches is 
probably the best strategy for drug discovery for neglected tropical diseases. This must be complemented 
by studies in animal models, which are reviewed in the final section of this chapter.
Synthetic compounds active against Trypanosoma cruzi and  
Trypanosoma brucei
Over the years, numerous papers have been published aiming at new, more effective and safe drugs with 
fewer side effects. In the context of this chapter, the synthesis and SAR studies of compounds with interesting 
biological activity are described, covering related literature from 2010 to the present. 
Quinoline derivatives 
A series of 10 2-alkylaminomethylquinoline derivatives were synthesized (Muscia et al. 2011) and 
were tested against different developmental stages of T. cruzi (epimastigotes, trypomastigotes and 
amastigotes). 
The interesting antiparasitic activity in vitro against epimastigotes of 5 compounds (IC50 = 3.4–11.8 μM 
vs 5.8 μM for benznidazole) led to further evaluation against trypomastigotes and amastigotes. Compound 
1 was the most active against trypomastigotes with IC50 = 3.1 μM, with cytotoxic activity against COS-7 
line slightly better than the reference drug (CC50 = 770.9 μM vs 706 μM for benznidazole). Furthermore, 
compound 1 showed good selectivity for both trypomastigotes and amastigotes with SI values of 248.7 
and 60.2, respectively. 
Reid et al. (2011) described the synthesis of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols 
(Figure 5) and their evaluation against T. brucei rhodesiense STIB900. The authors proceeded with an 
extensive SAR study in order to decipher the effect of the substituents on the biological activity. These 
studies are summarized in Figure 6. The most active compounds in vitro were 2, 3, 4 and 5 with IC50 values 
0.012 ± 0.001, 0.011 ± 0.001, 0.013 ± 0.004 and 0.014 ± 0.004 μM, respectively. These compounds were 
selected for in vivo evaluation and were administered to mice infected with T. brucei rhodesiense STIB900. 
Compound 2 suppressed parasitemia but a relapse occurred after 12.75 days after injection. Conversely, 
the ester prodrug 3 and the hydrochloride salts 4 and 5 resulted in cure even though at higher dosages 
(4 days × 50 mg/kg ip) than the reference drugs diminazene (4 days × 10 mg/kg ip) and pentamidine 
(4 days × 5 mg/kg ip). 
Hiltensperger et al. (2012) described the synthesis of a library of quinolone-type compounds bearing 
a benzamide function in position 3 and an amine heterocycle in position 7 (Figure 7) for SAR purposes. 
These compounds were tested against T. b. brucei and T. b. rhodesiense.
In the context of the SAR studies, synthetic intermediates were tested as well. It is apparent that 
the amidation at position 3 is essential for activity but only for benzylamide and not for phenylamide 
derivatives, indicating the necessity for flexibility in position 3. In addition, the presence of cyclic and 
acyclic amines at position 7 enhances the activity. The most potent compound proved to be compound 
6 which exhibited promising in vitro activity against T. brucei (IC50 = 47 nM) and T. b. rhodesiense 
(IC50 = 9 nM) combined with low cytotoxicity against macrophages J774.1. Hence, compound 6 was chosen 
for in vivo evaluation in a murine model of HAT. A preliminary formulation for oral administration was 
developed but was unsuccessful against T. b. rhodesiense (STIB900) infected NMRI mice.
Figure 4. Structure of the 2-alkylaminomethylquinoline derivative 1.
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Figure 5. Structures of most active N-benzyl-1,2-dihydroquinolin-6-ols 2–5.
Figure 6. Activity map of tested compounds (Reid et al. 2011).
Figure 7. Structure of the most potent compound 6.
Upadhayaya et al. (2013) described the synthesis of a series of compounds based on quinolines 
and indenoquinolines with variable side chains. From this library, five compounds (Figure 8) showed 
interesting activity. These compounds have shown better activity than benznidazole and nifurtimox 
(IC50 = 0.25–0.65 μΜ) against T. cruzi and T. brucei. 
A series of new 3-nitrotriazole and 2-nitrotriazole-linked quinolines and quinazolines were synthesized 
and their antitrypanosomal activity was tested (Papadopoulou et al. 2017). Even though almost all 
compounds showed activity against T. cruzi and T. b. rhodesiense, only 2 chloroquinoline derivatives 
(12 and 13, Figure 9) exhibited satisfactory selectivity indices. 
Particularly, compound 12 which bears a nitroimidazole moiety showed IC50 values of 1.29 and 
1.11 μM against T. b. rhodesiense and T. cruzi, respectively, while compound 13, which bears a nitrotriazole 
moiety, showed IC50 values of 0.038 and 0.574 μM, respectively. Especially compound 13 exhibited an 
excellent selectivity index against T. b. rhodesiense (SI = 1937).
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Diamines and polyamines 
Caminos et al. (2012) described the synthesis of 25 N,N’-disubstituted diamines through reductive amination 
of free aliphatic amines with various substituted benzaldehydes. This library was screened for antiparasitic 
activity in vitro against T. brucei and T. cruzi. In terms of SAR studies, the length of the aliphatic chain 
between the two amino functions was studied as well as the substitution of the benzyl moiety attached 
to the amines. The most promising compounds were 14 and 15 that bear a 4-OBn substitution and the 
aliphatic chain comprises 3 or 4 carbons (Figure 10). These compounds exhibit medium activity against 
T. cruzi (IC50 = 0.78 and 0.76 μM, respectively); however, they are significantly more active against 
T. brucei (IC50 = 0.062 and 0.097 μM, respectively) and with higher selectivity indices (SI = 97 and 60, 
respectively).
Sánchez-Moreno et al. (2012) published the synthesis of four pyrazole-containing macrocyclic and 
macrobicyclic polyamines and their in vitro and in vivo evaluation as potential antichagasic agents. Two 
of these compounds, 16 and 17 (Figure 11), were the most active from the compounds tested in T. cruzi 
epimastigote, axenic amastigote and intracellular amastigote forms. In addition, they proved to be more 
active than the reference drug benznidazole. More specifically, compound 16 showed an IC50 = 1.3 ± 0.1 
μM and compound 17 showed an IC50 = 1.3 ± 0.3 μM (versus benznidazole IC50 = 15.9 ± 1.1 μM) against 
the epimastigote form. Concerning the axenic epimastigote form, the IC50 values for compounds 16 and 
17 were 7.2 ± 2.2 μM and 8.8 ± 1.8 μM, respectively (benznidazole IC50 = 15.9 ± 1.1 μM). Finally, the 
Figure 8. Structures of quinoline (7–9) and indenoquinoline (10, 11) derivatives.
Figure 9. Structures of most potent chloroquinolines 12 and 13.
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IC50 values for compounds 16 and 17 were 6.2 ± 0.8 μM and 6.5 ± 1.6 μM, respectively, against the 
intracellular amastigote form, while for benznidazole, it was 23.3 ± 4.6 μM. Regarding the cytotoxicity 
evaluation, compounds 16 and 17 were substantially less toxic than the reference drug (IC50 = 149.1 and 
178.5 μM, respectively, against 13.6 μM for benznidazole).
Prompted by the in vitro results, these compounds were tested in vivo against female BALB/c mice 
and they proved to be more active than benznidazole in both the acute and chronic phase animal models.
Acridones 
A small library of acridones was synthesized and their antiparasitic activity was tested (Montalvo-Quirós 
et al. 2015). The most active compounds are depicted in Figure 12. Acridones 18–20 showed excellent 
activity against T. b. rhodesiense (IC50 = 0.069, 0.007 and 0.062 μM, respectively), accompanied by very 
good selectivity (SI > 2000). The N-methylation of these compounds to the corresponding acridones 
21–23 did not alter the activity of 22 and 23 but increased the activity of 21 10-fold (IC50 = 0.007 μM). 
Compounds 18–20 were chosen for preliminary in vivo evaluation in the T. b. rhodesiense mouse 
model. Compound 19 confirmed its activity since three out of four mice were cured, with mean day of 
relapse over fifty days. 
Thiohydantoins
During a high throughput screen for potential inhibitors of T. brucei in vitro, Buchynskyy et al. (2017a) 
discovered the substituted 2-thiohydantoin 24 (EC50 = 346 nM) as a potential hit compound. An extensive 
Figure 10. Structures of the most potent diamines 14 and 15. 
Figure 11. Structures of macrobicyclic and macrocyclic pyrazole-containing polyamines 16 and 17.
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SAR study which comprised changes to each of the phenyl moieties in terms of lipophilicity, site of 
substitution, electron donating and electron withdrawing groups and the combination of them, led to two 
new compounds 25 and 26 (Figure 13). These compounds showed excellent T. brucei activity in vitro 
(EC50 = 3 nM for 25 and EC50 = 2 nM for 26). For this purpose, they were also tested in vivo in the acute 
phase model of HAT. Both compounds cured all treated mice as no parasitemia was detected for 60 days 
after infection. 
Quinones, quinoxalines and quinazolines 
In recent years, naphthoquinone has drawn much attention as a scaffold with potential antitrypanosomatidic 
activity. Carneiro et al. (2012) reported the synthesis of new oxirane derivatives using naphthoquinones as 
starting materials. Even though most of the synthesized compounds proved more active than the reference 
drug benznidazole (IC50 = 11.5 μM, CC50 = 48 μΜ) in epimastigote forms of T. cruzi, only compound 27 
(Figure 14) exhibited comparable cytotoxicity (IC50 = 0.09 μM, CC50 = 44 μΜ). 
Khraiwesh et al. (2012) synthesized 11 new imido-substituted 1,4-naphthoquinones which were tested 
against T. cruzi epimastigotes. Interestingly, all compounds showed better activity (IC50 = 0.7–6.1 μM) 
than the reference drug nifurtimox (IC50 = 10.67 μM, SI = 10.86) but only 4 of them, compounds 28–31 
(Figure 15), exhibited a higher selectivity index (SI = 31.83–275.3). 
Figure 12. Acridones 18–23 with activity against T. b. rhodesiense.
Figure 13. Hit compound 24 and lead compounds 25 and 26.
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Figure 14. Structure of the most active oxirane derivative 27.
Figure 15. Structures of the most active imido-substituted 1,4-naphthoquinones 28–31.
Figure 16. Structures of the most active mono- and di-substituted naphthoquinones 32–34.
Samant and Chakaingesu (2013) synthesized a series of mono- and disubstituted naphthoquinones 
and all compounds were tested against T. b. rhodesiense. The most promising compounds are depicted in 
Figure 16. The monosubstituted compounds 33 and 34 were more active (IC50 = 0.07 ± 0.01 μM and 
0.05 ± 0.01 μM, respectively) than the disubstituted one (32) (IC50 = 0.09 ± 0.01 μM). In addition, 
these three compounds (32–34) were the least cytotoxic from this library, exhibiting values 88 ± 5 μM, 
75 ± 5 μM and 95 ± 5 μM, respectively, when tested against L-6 rat skeletal myoblast cells. 
A new library of aryloxy-quinone derivatives was synthesized (Vásquez et al. 2015). Interestingly, 
almost all new compounds were more active against T. cruzi epimastigotes and with better selectivity 
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index on murine macrophages J-774 cells than the reference drug nifurtimox (IC50 = 7.00 ± 0.3 μM, 
SI = 40). However, the combination of activity and selectivity led to four potential hits (Figure 17). 
Compound 35 was the most active (IC50 = 0.02 ± 0.01 μM, SI = 625) followed by compounds 36–38 with 
IC50 values 0.05 ± 0.02 μM, 0.04 ± 0.02 μM and 0.09 ± 0.04 μM, respectively. 
In the last decade, quinoxaline derivatives have been characterised as potential anti-trypanosomatid 
agents (Ancizu et al. 2009). Numerous compounds have been synthesized and evaluated and thus, some 
structural requirements have been established against trypanosomatids in vitro. Hence, the main structural 
requirements comprise the existence of the N-oxide moiety and the insertion of electron withdrawing 
groups on the quinoxaline ring. 
Benitez et al. (2011) synthesized an extensive library of quinoxalines N,N’-dioxides as potential anti- 
T. cruzi agents. Initially, the evaluation of these compounds was realized in vitro against the epimastigote 
form of the Talahuen 2 strain of T. cruzi by calculating the percentage of growth inhibition (PGI). The 
most active compounds were 39–47 (Figure 18). In addition, the ID50 concentrations (50% inhibitory 
dose) were assessed with the most active compounds being 39 (ID50 = 0.4 μM), 40 (ID50 = 0.7 μM) and 42 
(ID50 = 0.39 μM). Active compounds were also tested against two other T. cruzi strains, namely, colombiana 
and Y strains. In particular, the most potent compounds, 40 and 42, were tested in vivo in murine models 
of acute Chagas’ disease against the bloodstream trypomastigote form of T. cruzi, the CL Brener clone 
showing a very interesting biological profile. 
The aforementioned structural prerequisites concerning quinoxalines were confirmed by Torres et 
al. (2013). 18 new quinoxaline N,N’-dioxides were synthesized and evaluated against the epimastigote 
form of the Talahuen 2 strain of T. cruzi by calculating PGI. 14 out of 18 compounds showed PGI 
values of 100% while the most active compounds were 48–53 (Figure 19) with IC50 values varying from 
0.4–2.6 μM. Compound 52 was the most active compound (IC50 = 0.4 μM). 
Patel et al. (2013) described a repurposing effort for the approved human cancer drug lapatinib 
(54) towards the discovery of more potent growth inhibitors of T. brucei. After an extensive SAR study, 
4-anilinoquinazoline 55 (NEU-617) emerged as the most potent, orally bioavailable inhibitor of trypanosome 
replication (Figure 20). All compounds were tested against cultures of T. brucei brucei Lister 427. Compound 
55 (EC50 = 0.042 μM) was more active than lapatinib (EC50 = 1.54 μM) and it was even more selective 
against HepG2 cells (> 20 μM versus 6.2 μM for lapatinib). 
In an effort to further optimize 55 (NEU-617) as an antiparasitic lead compound, Devine et al. 
(2015) proceeded with the synthesis of new derivatives involving several replacements on the quinazoline 
scaffold. Even though 55 was superior against T. brucei compared to the new derivatives, several hits were 
discovered against other protozoal species, i.e., T. cruzi, L. major and P. falciparum. Thus, compound 56 
Figure 17. Structures of the most active aryloxy-quinones 35–38.
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Figure 18. Structures of the most active quinoxaline N,N’-dioxides 39–47.
Figure 19. Structures of the most active quinoxaline N,N’-dioxides 48–53.
Figure 20. Structures of lapatinib (54) and the most potent inhibitor 55.
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was found to be the most active compound against intracellular amastigotes of T. cruzi (EC50 = 0.09 μM) 
and compound 57 the most potent from the new library against T. brucei (EC50 = 0.21 μM) (Figure 21). 
Benzamide derivatives 
Based on their previous findings (Hwang et al. 2010), Hwang et al. (2013a) reported their optimization 
efforts for chloronitrobenzamides (CNBs). Compound 58 was found to be active against T. b. brucei 
(EC50 = 0.92 μM) and for that reason, a new SAR study was conducted which was aimed towards the 
discovery of new leads in which the chloronitrobenzamide moiety remained intact. Numerous compounds 
were synthesized and tested and finally compounds 59–61 were the most potent against T. b. brucei 
(EC50 = 0.006, 0.027 and 0.041 μM, respectively) (Figure 22). 
In addition, these compounds were tested against two other species, T. b. rhodesiense and 
T. b. gambiense. All compounds showed activity against T. b. rhodesiense (EC50 = 0.013, 0.007 and 
0.011 μM, respectively) as well as against T. b. gambiense (EC50 = 0.036, 0.002 and 0.001 μM, respectively). 
This fact indicates that there is no species variation concerning the sensitivity against CNBs. However, 
these compounds exhibited poor to modest solubility, an issue that should be addressed in their further 
development. 
In an effort to reduce complexity and molecular weight and at the same time, improve the 
pharmacological properties of CNBs, Hwang et al. (2013b) synthesized a new library of compounds 
by replacing the chloronitrobenzamide moiety. Even though most of the compounds were inactive, one 
potential lead (compound 62, Figure 23) was found which bears the 4-chloropyridine carboxamide moiety. 
This compound showed good activity against T. b. brucei (EC50 = 0.12 μM) and excellent activity against 
T. b. rhodesiense (EC50 = 0.018 μM) and T. b. gambiense (EC50 = 0.038 μM). 
Pyridyl benzamides were further explored as potential anti-trypanosomatidic agents (Ferrins et al. 
2014). An extensive SAR study was conducted based on hit compound 63 (IC50 = 3.03 μM). A large 
library was synthesized and tested against T. b. brucei, T. b. rhodesiense and T. cruzi. Compounds 64–68 
(Figure 24) showed activity with IC50 values ranging between 0.41–1.1 μM against T. b. brucei and 
0.045–0.64 μΜ against T. b. rhodesiense, with the most active compound being 65 (IC50 = 0.045 μM). 
However, all compounds were inactive against T. cruzi. These compounds with low molecular weight 
have favorable properties for further optimization and have a very good prediction for CNS penetration 
which is essential for treating second stage HAT.
In the context of a high throughput screening campaign of 87000 compounds against T. b. brucei, 
Rahmani et al. (2015) identified a new class of potential trypanocides, pyrazine carboxamides. This screening 
delivered a starting hit, compound 69 (EC50 = 0.49 μM) and subsequent SAR studies were conducted 
concerning structural changes around the core. Several compounds showed very good activity against 
T. b. brucei and T. b. rhodesiense but the most active compounds were 70 with EC50 values of 0.035 and 
0.024 μM against T. b. brucei and T. b. rhodesiense, respectively and compound 71 with EC50 values 
0.025 and 0.038 μM, respectively (Figure 25). Worth mentioning is that this class of compounds showed 
Figure 21. Structures of the most potent inhibitors 56 and 57.
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Figure 22. Structures of hit compound 58 and the most potent CNBs 59–61.
Figure 23. Structure of lead compound 62.
Figure 24. Structures of hit compound 63 and lead pyridyl benzamides 64–68.
Figure 25. Structures of hit compound 69 and lead compounds 70 and 71.
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very low cytotoxicity and was selective for T. brucei, since no significant activity was observed against 
T. cruzi.
Cleghorn et al. (2015) conducted a phenotypic screening of compounds against T. b. brucei followed 
by a mammalian cell counterscreen (MRC-5 cells) to exclude nonselective compounds. This work led to 
indoline-2-carboxamide 72 (Figure 26) which showed good activity (EC50 = 27 nM) and selectivity over 
mammalian cells (> 1600 fold). With compound 72 in hand, SAR studies were realized in terms of core 
modifications and the effect of stereochemistry on the chiral center. These studies led to the discovery of 
two new compounds, 73 and 74 (racemic), with lower activity against T. b. brucei (EC50 = 60 and 80 nM, 
respectively) but with improved metabolic stability and enhanced in vivo exposure. These compounds 
exhibited excellent pharmacokinetic properties, and resulted in a full cure in a HAT stage 1 mouse model, 
but unfortunately only a partial cure in stage 2.
Buchynskyy et al. (2017b) identified N-(2-aminoethyl)-N-phenyl benzamides as an interesting class of 
compounds with potential antiparasitic activity against T. brucei. Compound 75 (Figure 27) was selected 
as a hit compound for its activity (EC50 = 1.21 μM) against T. b. brucei, its selectivity over mammalian 
cells (> 30 fold) and its drug-like features, including low molecular weight, clogP, H-bond donors and 
acceptors. The outcome of SAR studies was the discovery of some new lead compounds with EC50 
values ranging from 0.001–0.031 μM with compound 76 being the most potent (EC50 = 0.001 μM against 
Figure 26. Structures of potent indoline-2-carboxamides 72–74.
Figure 27. Structures of hit compound 75 and lead compound 76.
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T. b. brucei and 0.002 μM against T. b. rhodesiense). However, in murine efficacy models of HAT infection, 
the compounds showed only partial cures or suppression. 
Chalcones 
Chalcones form another class of compounds with broad spectrum pharmacological activities. Recently, 
Borsari et al. (2017) reported the synthesis of a library of thirteen 2-hydroxy chalcones bearing methoxy 
groups. All the synthesized compounds were tested against the bloodstream form of T. brucei and the 
intracellular T. cruzi at 10 mM. Compounds 77–79 (Figure 28) were the most potent against T. brucei with 
EC50 values 1.3 ± 0.02, 2.1 ± 0 and 2.1 ± 0.4 μΜ, respectively and with selectivity index > 12. 
Bhambra et al. (2017) synthesized a small library of pyridylchalcones which were tested against 
T. b. rhodesiense. Even though none of these compounds showed better activity than the reference drugs 
pentamidine or melarsoprol, three compounds (80–82) can be considered as potential leads with IC50 values 
0.29, 0.40 and 0.41 μM, respectively (Figure 29). 
Hydroxamic acid derivatives 
Fytas et al. (2011) discovered acetohydroxamic acids as a new class of compounds with potential 
antitrypanocidal activity. The synthesis of these compounds was realized through the attachment of an 
acetohydroxamic acid moiety to the imidic nitrogen of 2,6-diketopiperazines. A SAR study revealed that 
compounds 83 (S-enantiomer), 84 (R-enantiomer) and 85 (racemic mixture of 83 and 84) (Figure 30) 
showed low nanomolar activity against bloodstream-form T. brucei with IC50 values 6.8 ± 1.4, 9.1 ± 0.2 
and 17± 1 nM, respectively, while compound 83 along with compounds 86 and 87 displayed significant 
activity against T. cruzi with IC50 values 0.21 ± 0.04, 5.51 ± 0.68 and 3.62 ± 0.31 μM, respectively. Overall, 
compound 83 proved to be the most active compound against both species. In addition, these compounds 
showed very good selectivity indices. The fact that replacement of the hydroxamic acid moiety led to 
compounds with decreased activity makes this group a requisite for trypanocidal activity. 
A small library of hydroxamic acid derivatives which inhibit human histone deacetylases was 
synthesized and tested against cultured bloodstream form T. brucei (Kelly et al. 2012). Most of these 
compounds exhibited very good activity in the submicromolar range. Specifically, the most promising 
compounds were 88–90 (Figure 31) with IC50 values 0.034 ± 0.002, 0.064 ± 0.005 and 0.086 ± 0.009 μM, 
respectively. 
Thiazole derivatives
Zelisko et al. (2012) described the synthesis and biological evaluation of a series of 6,6,7-trisubstituted 
thiopyrano[2,3-d][1,3] thiazoles. Interestingly, one compound, 91 (Figure 32), inhibited T. b. brucei and 
Figure 28. Structures of the most potent methoxylated 2-hydroxychalcones 77–79.
Figure 29. Structures of most potent pyridylchalcones 80–82.
202 Medicinal Chemistry of Neglected and Tropical Diseases
Figure 30. Structures of hydroxamic acids 83–87.
Figure 31. Structures of the most active hydroxamic acids 88–90.
Figure 32. Structure of potential lead 91.
T. b. gambiense with IC50 values 0.26 and 0.42 μM, respectively; thus, it can be considered as a potential 
lead for further optimization. 
Cardoso et al. (2014) reported the synthesis and the anti-T. cruzi activity of 24 2-(pyridine-2-yl)-1,3-
thiazoles by ultrasound-assisted synthesis. The majority of this class of compounds demonstrated better 
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activity than the reference drug benznidazole, with compounds 92 and 93 (Figure 33) being the most 
potent with IC50 values 1.2 μM each against T. cruzi trypomastigotes. In addition, this class of compounds 
showed no cytotoxicity against HepG2 cells. 
Russell et al. (2016) published their work on hit to lead optimization of compound 94 (Figure 34). 
The latter emerged as a hit compound through a high-throughput screening because it exhibited interesting 
activity (IC50 = 0.80, 1.5 and 2.3 μM for T. b. brucei, T. b. rhodesiense and T. cruzi, respectively) and 
very good physicochemical properties. An extensive SAR study was conducted towards the discovery of 
new leads. Indeed, 2-(fluorophenyl)thiazole 95 was found to exhibit excellent activity against T. b. brucei 
(IC50 = 0.024 ± 0.003 μM, SI = 433) and T. cruzi (IC50 = 0.020 ± 0.01 μM, SI > 3162). Compound 95 was 
tested in vivo in Balb/c mice infected with the trypomastigote form of T. cruzi Brazil strain with encouraging 
results but unfortunately it was rapidly metabolized.
In a phenotypic high-throughput screening of 700,000 compounds, compound 96 (Figure 35) 
was identified, among others, as a potential inhibitor of T. brucei (IC50 = 0.632 μM, SI = 162 against 
T. b. rhodesiense). Patrick et al. (2016, 2017) with two back-to-back papers reported the efforts towards 
the optimization of a hit compound. A SAR study was conducted by focusing on changes to both phenyl 
rings of compound 96. Therefore, 72 new derivatives were synthesized and tested against T. b. rhodesiense 
STIB900 and L6 rat myoblast cells for cytotoxicity in vitro. 44 compounds were more active than 96 
and eight of them showed IC50 values below 100 nM. The most potent compound was 97 (IC50 = 9 nM, 
SI > 18,000) but unfortunately, the in vivo test showed that it was unable to cure infected mice. Even 
though the administration of 97 caused reduction of parasitemia, relapses occurred. This was attributed 
to poor metabolic stability. Prompted by these results, a second paper described a new SAR study of 65 
Figure 34. Structures of hit compound 94 and lead compound 95.
Figure 35. Structures of hit compound 96 and lead compounds 97 and 98.
Figure 33. Structures of most potent thiazole derivatives 92 and 93.
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additional compounds with modifications in other sites on hit 96 with the intention of maintaining the 
same activity and improving the metabolic stability. This led to compound 98 which was less active than 
97 (IC50 = 35 nΜ) but with enhanced metabolic stability and brain penetration. Oral dosing of 98 cured 
five out of five mice in both acute and chronic murine models of HAT. 
Many thiazole derivatives were synthesized and evaluated for their antiparasitic activity during the last 
year by several research groups. Compound 99 (Filho et al. 2017) showed activity against the promastigote 
form of T. cruzi (IC50 = 0.37 μM), compound 100 (Thompson et al. 2017) with IC50 = 0.055 μM against 
T. cruzi, and compounds 101 and 102 (Silva et al. 2017) with IC50 values 1.2 and 1.6 μM, respectively 
against the trypomastigote form of T. cruzi (Figure 36).
Thiophene derivatives 
Bhambra et al. (2016) reported the synthesis of a small library of 2,6-disubstituted-4,5,7-
trifluorobenzothiophenes. Compounds 103 and 104 (Figure 37) demonstrated interesting antitrypanosomal 
activity against T. b. rhodesiense with IC50 values 0.60 and 0.53 μM, respectively and no toxicity to 
mammalian cells. It is apparent that the activity of these compounds can be attributed to the existence of 
the benzimidazole moiety since its replacement resulted in loss of activity. 
Indole derivatives 
Vega et al. (2012) prepared a series of nitro-indazolin-3-ones which were tested in vitro against epimastigote 
forms of T. cruzi. Compounds 105–107 (Figure 38) showed interesting trypanocidal activity (IC50 = 0.93, 
2.39, 1.17 μM, respectively) and low unspecified toxicity. The authors found structural similarities with 
other known antiprotozoan drugs during their search, and therefore they introduced a new scaffold for 
further research and optimization. 
Tapia et al. (2014) synthesized a series of indole-4,9-dione and their activity was evaluated against 
the epimastigote form of T. cruzi, Y strain. All new compounds showed better activity and selectivity 
compared to the reference drug nifurtimox. Interestingly, compound 108 (Figure 38) demonstrated excellent 
nanomolar inhibitory activity (IC50 = 20 nM), and high selectivity index (SI = 625). 
Imidazole derivatives 
A high-throughput screening of 303,286 compounds revealed a class of imidazole-based inhibitors 
(109–111, Figure 39) that can inhibit infection of mammalian host cells by T. cruzi trypomastigotes 
(Bettiol et al. 2009). In an effort to further optimize the activity, cytotoxicity and bioavailability, new 
Figure 36. Structures of potential hits 99–102.
Hits and Lead Discovery in the Identification of New Drugs against the Trypanosomatidic Infections 205
Figure 37. Structures of potential hits 103 and 104.
Figure 38. Structures of indole derivatives with potential trypanocidal activity.
Figure 39. Structures of hit compounds 109–111 and lead compounds 112 and 113.
inhibitors of T. cruzi CYP51 were synthesized (Andriani et al. 2013) with ring-constrained structures. The 
most promising inhibitors were 112 (EC50 = 72 nM) and 113 (EC50 = 80 nM). 
The SAR study revealed that the substitution of the phenyl ring with lipophilic groups is essential. The 
absence of these groups was accompanied by loss of potency. In addition, replacement of the imidazole 
moiety by other nitrogen heterocycles, such as pyrazole or triazole, resulted in loss of activity. Hence, the 
presence of an imidazole ring is required for T. cruzi CYP51 binding. 
More compounds bearing an imidazole ring have been synthesized and tested against the drug-
targetable enzyme CYP51 due to structural similarities with its inhibitors. In particular, compounds 
114–116 (Figure 40), even in their racemic form, showed very interesting biological activity against 
T. cruzi Talahuen C2C4 amastigote stage (Friggeri et al. 2013) with IC50 values 14, 5 and 36 nM, 
respectively. The authors wanted to further explore the activity of the single enantiomers which led to the 
conclusion that S-enantiomers were more active than the corresponding R-enantiomers. Compound (S)-114 
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Figure 41. Structures of the most active dialkylimidazoles 117–122.
Figure 40. Structures of active compounds 114–116.
showed IC50 = 3.8 nM vs 193 nM of (R)-114, (S)-115 showed IC50 = 1.8 nM while (R)-115 showed 
IC50 =112 nM and (S)-116 showed IC50 = 23.6 nM vs 97.2 nM of (R)-116.
Suryadevara et al. (2013) described the synthesis of 75 dialkylimidazole-imidazole based inhibitors 
of CYP51. Interestingly, most of the compounds showed remarkable nanomolar activity against T. cruzi 
amastigotes. The most promising compounds and their EC values are depicted in Figure 41. 
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Computational and experimental structure-based drug design strategies 
against Trypanosoma cruzi and Trypanosoma brucei
In the above section, we presented a large number of synthetic compounds that have been optimized 
for their anti-trypanosomal properties; however, this was often done without taking specific molecular 
targets into account. Target-oriented methods provide an alternative strategy or can present an interesting 
complement to optimization based solely on anti-parasitic properties. In this section, we review some of 
the recent literature on structure-based drug design (SBDD) efforts to tackle trypanosomatidic infections by 
targeting specific metabolic pathways or enzymes that have been extensively explored in target-guided drug 
discovery approaches during the past years, such as CYP51, folate pathway proteins, phosphodiesterases, 
cysteine proteases or enzymes of the trypanothione metabolism. In the discovery of new hits and lead 
optimization, experimental methods and computational techniques are widely used together to facilitate 
the process of compound library design and iterative improvement in the context of known (or predicted) 
biomolecular targets. We describe approaches to SBDD for key targets, as well as techniques for tackling 
typical challenges in SBDD, such as selectivity, off-target binding and deciphering the mechanism-of-
action (MoA) of a drug. We conclude the section with a brief summary of the methods typically employed 
in anti-trypanosomatidic drug discovery, their potential applications and limitations.
Compounds targeting the lanosterol 14α-demethylase (CYP51)
A particularly prominent example of a widely considered anti-trypanosomatid drug target is an enzyme 
involved in the ergosterol biosynthesis route, namely the lanosterol 14α-demethylase (or CYP51). 
CYP51s, which belong to the family of cytochrome P450s, are highly conserved heme-containing proteins 
involved in the production of plasma membrane building blocks and regulatory molecules (Lepesheva 
and Waterman 2004, 2007). Azole-based CYP51 inhibitors are known anti-fungal agents (Lass-Flörl 
2011, Denning and Bromley 2015) and the trypanosomal ergosterol biosynthesis resembles that of fungi, 
making the repurposing of anti-fungal compounds a well-explored design strategy (Buckner and Urbina 
2012). Furthermore, crystallographic complexes of TbCYP51 and TcCYP51 with anti-fungal compounds, 
such as fluconazole 123 and posaconazole 124 (Figure 42, Chen et al. 2010), paved the way for further 
optimization of azole-based and chemically distinct CYP51 inhibitors for trypanosomatidic infections. 
As another example, Hoekstra et al. (2015) reported the crystallographic complex of a 1-tetrazole-based 
anti-fungal clinical drug candidate with TcCYP51, providing an additional target-based starting point for 
future optimization of the compound as an anti-Chagas agent.
Figure 42. Interaction diagrams of the anti-fungal compounds fluconazole 123 (left) in TcCYP51 and posaconazole 124 
(right) in TbCYP51. The diagrams are based on the crystallographic complexes with PDB-ID 2wuz and 2x2n (Chen et al. 
2010), respectively. Pocket-lining residues and the pocket shape are shown. Black dashed lines indicate coordination bonds 
between the ferric heme iron and a nitrogen atom of the ligand, gray dotted lines indicate π-π interactions and black arrows 
indicate hydrogen-bonding interactions.
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Hargrove et al. (2013) used X-ray crystallography to determine the binding modes of the promising 
pyridine-based drug candidates 125 and 126 (Figure 43) for Chagas disease. These compounds were 
found to be the first non-azole compounds showing potent inhibition of TcCYP51 as posaconazole 124. 
Importantly, the structural data show that the coordination bond between the pyridine heterocycles of 125 
and 126 and ferric heme iron of TcCYP51 are longer than in the case of azoles. The authors highlight that 
this may allow for achieving higher selectivity between the trypanosomal enzyme and the human variant 
since, due to the weaker coordinating interaction, the other non-bonded interactions between the protein 
and the ligand, which differ between the targets, become more important determinants for compound 
binding affinities. However, as can be seen in Figure 43, the interaction of compounds 125 and 126 with 
TcCYP51 is mainly mediated by hydrophobic contacts.
The development of the aforementioned imidazole-based T. cruzi CYP51 inhibitors 112 and 113 
(see Figure 39) by Andriani et al. (2013) as well as compounds 114–116 (Figure 40) by Friggeri et al. 
(2013) was similarly supported by crystallographic data (directly by structure determination or indirectly by 
docking studies to existing crystal structures). In a follow-up study, Friggeri et al. (2014) further optimized 
imidazole-based inhibitors and demonstrated their ability to bind to CYP51 in two different regions: either 
in the substrate-binding site close to the heme group or in the substrate access channel (compare binding 
mode of 127 in Figure 44).
Another example of a particularly successful SBDD approach is the drug candidate (R)-N-(1-(3,4’-
difluorobiphenyl-4-yl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide (128, 
Figure 45) developed by Lepesheva et al. (2015). Based on 127, which cured both acute and chronic 
Chagas disease in experimental models, and the existing structural knowledge for CYP51 (Lepesheva 
et al. 2010, Villalta et al. 2013), 128 was designed as a highly specific inhibitor of the trypanosomal 
enzyme by introducing additional aromatic interactions between the protein and the ligand in the depth 
of the CYP51 binding cavity (see Figures 44 and 45). 128 displayed an improved anti-parasitic activity 
(EC50 against T. cruzi amastigotes from infected cardiomyocytes 0.8 nM for 128 vs. 1.3 nM for 127), cures 
experimental Chagas disease with 100% efficiency, is orally bioavailable and has low off-target activity 
as well as favorable pharmacokinetics.
Not only crystallography but also docking studies were employed in the design of CYP51 inhibitors. 
More recently, docking of imidazoles (De Vita et al. 2016) and pyrazolo[3,4-e][1,4]thiazepin-based 
inhibitors (Ferreira de Almeida Fuiza et al. 2018) against TcCYP51 crystal structures identified this enzyme 
as a potential target, which rationalized the observed anti-T. cruzi activities of the compounds.
An interesting complement to the efforts guided solely by static crystal structures are molecular 
dynamics (MD) simulations, performed by Yu et al. (2015, 2016), used to study ligand egress routes in 
Figure 43. Interaction diagrams of two pyridine-based inhibitors of TcCYP51, 125 and 126. The diagrams are based on the 
crystallographic complexes with PDB-ID 3zg2 and 3zg3 (Hargrove et al. 2013), respectively. Pocket-lining residues and the 
pocket shape are shown. Black dashed lines indicate coordination bonds between the ferric heme iron and a nitrogen atom of 
the ligand and gray dotted lines indicate π-π interactions.
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T. brucei CYP51 in comparison with human CYP51. These studies highlight differences in the dynamics 
and composition of the ligand tunnel between the trypanosomal and human CYP51, which could be 
exploited in the future anti-parasitic drug design efforts to enhance selectivity.
Gunatilleke et al. (2012) combined target-based high-throughput screening (HTS) with a screen against 
T. cruzi-infected skeletal myoblast cells to yield compounds with a known molecular target and activity 
against the parasite. Further, they used bioinformatics approaches to demonstrate similarities between 
compounds preferentially bound by CYP51 and compounds bound by several other cytochrome P450 
enzymes and an unrelated glutaminyl-peptide cyclotransferase. Inhibitors of these enzymes can hence 
serve as a potential pool of lead compounds.
It is not uncommon that large libraries of potential hit compounds are screened in silico against large 
crystallographic databases of enzymatic targets. A drawback of such screens is that many studies lack 
experimental validation of their results. Nevertheless, in silico studies exploring, for example, potential 
Figure 45. Interaction diagrams of two inhibitors of TbCYP51, 127 and its optimized derivative 128. The diagrams are based 
on the crystallographic complexes with PDB-ID 3gw9 and 4g7g (Lepesheva et al. 2010, 2015), respectively. Pocket-lining 
residues and the pocket shape are shown. Black dashed lines indicate coordination bonds between ferric heme iron and a 
nitrogen atom of the ligand, gray dotted lines with filled circles indicate π-π interactions, gray dotted lines with white circles 
cation-π interactions and black arrows show hydrogen-bonding interactions.
Figure 44. Compound 127 binding to TcCYP51 (see also Figure 42, based on PDB-ID 3gw9; Lepesheva et al. 2010), occupying 
the substrate access channel and coordinating with the ferric heme iron. The protein is shown as a semi-transparent surface 
with the ligand in black and the heme group in white sticks. The channel opening towards the surface is marked. On the right 
side, the protein was removed for clarity. One part of the ligand binds to the channel, while a second portion forms additional 
interactions in the depth of the pocket. The top view was rotated by approx. 45° to show the coordination between the ligand 
and the ferric heme iron in the lower panel.
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targets of phytochemicals may provide some first insight when a target is not known or may be used to 
propose possible hits for a desired target. For example, compounds isolated from Nigerian medicinal plants 
have been studied by Setzer and Ogungbe (2012). They found in silico potential inhibitors of, amongst 
others, TbCYP51 and two enzymes of the parasitic folate pathway: pteridine reductase 1 (PTR1) and 
dihydrofolate reductase (DHFR). 
Further details on the current structural knowledge about CYP51 in trypanosomatids and the design 
of inhibitory compounds can be found in the recent review by Lepesheva et al. (2018).
Folate metabolism
Targeting the kinetoplastid folate pathway, unlike the corresponding malarial (Hawser et al. 2006) and 
bacterial (Yuthavong et al. 2005) pathways, requires not only the inhibition of dihydrofolate reductase 
(DHFR), but also of pteridine reductase 1 (PTR1) (Bello et al. 1994, Sienkiewicz et al. 2010). The latter 
enzyme is mainly responsible for the reduction of pterins, but can be upregulated when DHFR is inhibited 
and serve as a bypass for folate reduction to provide necessary educts for DNA synthesis and thus ensure 
parasite survival (Dawson et al. 2006, Vickers and Beverley 2011). In T. brucei, PTR1 was validated as a 
potential drug target by the gene knockout and RNA interference experiments (Ong et al. 2011, Sienkiewicz 
et al. 2010). Herein, we mostly focus on inhibitor design for PTR1 from T. cruzi and T. brucei. Multiple 
drug design approaches have been used to target PTR1, starting from optimization of the substrate scaffold, 
through virtual screening (VS), to fragment-based drug design (FBDD).
An example of a classical substrate-like compound is methotrexate 129 (MTX), which is a 
subnanomolar inhibitor of DHFR, and an approved anti-cancer drug (Zuccotto et al. 1999, Shuvalov et 
al. 2017). However, it has also been shown to inhibit PTR1 at the sub-micromolar level (Dawson et al. 
2006, Cavazzuti et al. 2008). Notably, the substrate, MTX and most other inhibitors of PTR1 occupy 
the main binding site in a π-sandwich between the nicotinamide of the NADPH/NADP+ cofactor and a 
phenylalanine residue (Figure 46). MTX adopts a similar binding mode to folate 130, but with a flipped 
orientation of the pteridine ring (Figure 46).
The aformentioned binding modes of folate and MTX were starting points in the study by Tulloch et al. 
(2010), who selected 3 scaffolds—pteridine, pyrrolopyrimidine and pyrimidine—for inhibitor design and 
optimization against T. brucei PTR1 (TbPTR1). Five pyrrolopyrimidine-based inhibitors were identified 
and crystallized in TbPTR1. Among those, 131 and 132 (Figure 47) with Ki values against TbPTR1 of 
0.36 μM and 0.40 μM, respectively, were found to attain modest ED50 values against the T. brucei 
bloodstream form (BSF): 274 ± 7.5 μM and 123 ± 3.3 μM, respectively. 132 was also found to show 
a synergistic effect when combined with MTX. Later, Khalaf et al. (2014) used a similar approach for 
the development of 61 additional pyrrolopyrimidines, of which 23 were crystallized in TbPTR1, greatly 
expanding the structural data available for this enzyme. Two of the crystallized compounds, 133 and 134 
(Figure 48), had TbPTR1 Ki
app values of 0.23 μM and 0.14 μM, respectively, and were found to have 
T. brucei BSF IC50 values of 3.20 μM and 0.25 μM, respectively, in Creek’s minimal medium. However, 
these derivatives showed substantial toxicity in in vivo mouse models and thus were not suitable for 
further development.
VS approaches were used to identify novel non-pteridine scaffolds, including the 2-aminothiadiazole 
core and flavonoids as potential binders of the PTR1 substrate pocket (Ferrari et al. 2011, Borsari et al. 
2016). Recently, a library of 2-aminothiadiazole-based TbPTR1 inhibitors has been developed (Linciano 
et al. 2017). X-ray crystallography and docking simulations confirmed the classical binding mode for these 
series (cf. Figure 46), with the amino moiety of the scaffold core interacting with a serine residue close 
to the active site, cofactor ribose and phosphates (Figure 49). Two thiadiazole-2,5-diamines 136 and 137 
(Figure 49) reached TbPTR1 IC50 values of 16.0 μM and 25.0 μM, respectively. Despite being unable to 
inhibit the T. brucei BSF as single agents, both PTR1 inhibitors potentiated the EC50 of MTX by 4.1 and 
2-fold, respectively.
Another class of hits against PTR1 were flavonoids, identified by computational and experimental 
screening of a natural products library (Borsari et al. 2016), with flavonols showing the most promising 
inhibitory effect on TbPTR1. A combination of crystallographic experiments and computational docking 
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was then employed to explore the multiple possible binding modes and deduce a structure-activity 
relationship (SAR) for a set of synthetic flavonols. In a follow-up project, the same methods allowed 
in-depth characterization of the determinants of the activities of several flavonols and the corresponding 
flavanones (Di Pisa et al. 2017).
In another VS study, Dube et al. (2014) used a combination of docking and pharmacophore modeling 
to screen the ZINC database for putative inhibitors of TbPTR1 and predict their activities. The VS of 
Figure 47. Interaction diagrams of two pyrrolopyrimidine-based inhibitors of TbPTR1, 131 and 132. The diagrams are based 
on the crystallographic complexes with PDB-ID 3jqe and 3jq9 (Tulloch et al. 2010), respectively. Pocket-lining residues and 
the pocket shape are shown. Gray dotted lines indicate π-π interactions and black arrows show hydrogen-bonding interactions. 
NAP denotes NADP(H).
Figure 46. Illustration of compounds binding in the π-sandwich between Phe97 and the nicotinamide of the NADPH/
NADP+ cofactor of TbPTR1. On the left, a monomer of the homotetrameric enzyme is shown as a semi-transparent surface 
representation with bound MTX 129 in dark ball-and-stick representation and the cofactor and Phe97 in white sticks. In the 
right-hand panel, the same representation is used, omitting only the protein. The complex with MTX 129 is based on PDB-ID 
2c7v (Dawson et al. 2006), with folate 130—on PDB-ID 3bmc (Tulloch et al. 2010) and with 138, illustrating the non-classical 
binding mode outside the π-sandwich—on PDB-ID 3gn2 (Mpamhanga et al. 2009).
color version at the end of the book
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fragments against TbPTR1 performed by Mpamhanga et al. (2009) identified 2-aminobenzothiazole 
and 2-aminobenzimidazole, binding in the substrate pocket, as promising cores that were further used 
for inhibitor development. Notably, the crystallographic studies revealed that some of the synthesized 
compounds with a 2-aminobenzimidazole scaffold adopted a non-classical binding mode in the TbPTR1-
specific subsite adjacent to the primary substrate binding site (Mpamhanga et al. 2009; Figure 46, 
compound 138). Compounds 138 and 139 (Figure 50) reached Ki
app
 of 0.4 μM and 0.007 μM, respectively, 
against TbPTR1. Despite its nanomolar on-target potency, 138 displayed an EC50 against T. brucei of only 
10 μM. Spinks et al. (2011) further attempted to optimize the series of 2-aminobenzimidazoles to 
target the alternative subsite, but anti-parasite activities did not improve, with the lowest EC50 value being 
6.7 μM.
The non-classical binding mode of the amino-benzimidazole series discussed above inspired 
computational FBDD studies to combine a scaffold with a classical binding mode with an alternative 
subpocket-targeting scaffold. In principle, computational methods exist that may help in finding the best 
molecular fragment binding the subsite. However, in the case of the TbPTR1 alternative subsite exploited 
by Mpamhanga et al. (2009) and Spinks et al. (2011), this was challenging due to the presence of halogen 
substituents in the most potent compounds. Many state-of-the-art commonly used force fields used in 
Figure 49. Interaction diagrams of a 2,5-diamino-1,3,4-thiadiazole inhibitor of TbPTR1, 135 and structures of its derivatives 
136 and 137. Compounds 136 and 137 were predicted to show a similar binding mode in TbPTR1 by docking studies (Linciano 
et al. 2017). The interaction diagram is based on the crystallographic complex with PDB-ID 5izc. Pocket-lining residues and 
the pocket shape are shown. Gray dotted lines indicate π-π interactions and black arrows show hydrogen-bonding interactions. 
NAP denotes NADP(H).
Figure 48. Interaction diagrams of two additional pyrrolopyrimidine-based inhibitors of TbPTR1, 133 and 134. The diagrams 
are based on the crystallographic complexes with PDB-ID 4cmi and 4cmj (Khalaf et al. 2014), respectively. Pocket-lining 
residues and the pocket shape are shown. Gray dotted lines indicate π-π interactions and black arrows show hydrogen-bonding 
interactions. NAP denotes NADP(H).
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molecular docking suffer from short-comings in the representation of halogens (Wilcken et al. 2013). Thus, 
using the 2-aminobenzimidazole series by Mpamhanga et al. (2009) and Spinks et al. (2011), Jedwabny et 
al. (2017) demonstrated how a computationally efficient quantum-mechanics-based model for predicting 
binding affinities of fragments in the TbPTR1 binding site could be used to overcome these issues.
The majority of compounds have been developed to target TbPTR1 (or Leishmania major PTR1). 
Although a crystal structure of a close homolog of TcPTR1, TcPTR2, was solved (Schormann et al. 
2005), most drug design efforts did not consider the T. cruzi enzyme variants. Mendoza-Martı́nez et al. 
(2015) designed some quinazoline derivatives and used docking studies to support TcPTR2 and TcDHFR 
as reasonable potential targets. The compounds were evaluated against bloodstream trypomastigotes of 
two strains of T. cruzi (NINOA and INC-5 strain) and compounds 140–142 (Figure 51) were found to be 
particularly interesting, since they showed a better activity profile than the reference drugs, nifurtimox 
and benznidazole.
Otherwise, for T. cruzi, mainly DHFR was considered in drug design efforts: Schormann et al. (2008) 
used 3D-QSAR models to guide the design of inhibitors selective for TcDHFR over human DHFR (hDHFR). 
In the subsequent study, guided by crystallography and docking experiments, they exploited amino acid 
Figure 50. Interaction diagrams of two 2-aminobenzimidazole-based inhibitors of TbPTR1 binding in a non-classical binding 
mode, 138 and 139 (cf. also Figure 46). The diagrams are based on the crystallographic complexes with PDB-ID 3gn2 and 
2wd8 (Mpamhanga et al. 2009), respectively. Pocket-lining residues and the pocket shape are shown. Gray dotted lines indicate 
π-π interactions, black arrows show hydrogen-bonding interactions and gray arrows indicate halogen-bonds.
Figure 51. Structures of the quinazoline derivatives 140–142 that putatively target TcPTR2/TcDHFR.
214 Medicinal Chemistry of Neglected and Tropical Diseases
differences between the pocket entrance regions of hDHFR and TcDHFR, including the substitution of 
Phe31 to Met49. A series of 2,4-diaminoquinazoline derivatives, similar to trimetrexate, with varying 
flexible hydrophobic groups in the tail, some of which bound near Met49 of TcDHFR, had about 7–8 
times better Ki against TcDHFR than hDHFR (Schormann et al. 2010). 
The above discussed study of Mendoza-Martı́nez et al. (2015) is an example of a dual inhibition 
approach, which is particularly important for targeting the trypanosomatid folate pathway. Ideally, this 
requires targeting both PTR1 and parasitic DHFR, while avoiding inhibitor binding to hDHFR, which is 
quite similar to the parasitic homologue. To address this issue, Panecka-Hofman et al. (2017) applied a 
variety of techniques (such as computational analysis of crystallographic structures, homology modeling 
and binding site mapping) for sequence and structural comparison of the folate pathway on- and off-
targets. Ligand-target interactions, binding site properties and target conformational variability were 
computationally compared to yield guidelines for the design and optimization of selective inhibitors of 
the trypanosomatidic folate pathway. In an extension of this study, the conformational variability of the 
TcDHFR and hDHFR binding sites was analyzed with the TRAPP (TRAnsient Pockets in Proteins) web 
server based on the available crystallographic data (Stank et al. 2017). Complementary to the aforementioned 
work of Schormann et al. (2010), a transiently appearing subpocket was identified in the vicinity of Met49, 
which corresponds to Phe31 in hDHFR. The ProSAT+ tool integrated in TRAPP also identified position 
31 as a known site of an hDHFR mutation that alters binding of the MTX inhibitor.
The majority of drug design efforts for the kinetoplastid folate pathway have so far focused on PTR1/
PTR2 and DHFR. A few other folate pathway enzymes, such as the N5,N10-methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase (DHCH) of T. brucei, were considered in compound development. Eadsforth 
et al. (2015) designed inhibitors of TbDHCH using a combination of crystallographic and docking 
experiments starting from an inhibitor of bacterial and human DHCH.
Despite the extensive design and development efforts to obtain potent and selective inhibitors of 
PTR1 and DHFR, there is often limited transferability of on-target-based activity to an in vitro or even 
in vivo activity against T. brucei or T. cruzi. For a more detailed overview on the efforts made, possible 
reasons for this limitation and other potential targets to be considered in the future, the reader is referred 
to the recent review by Cullia et al. (2018).
Phosphodiesterases
More recently, a phosphodiesterase (PDE) of T. brucei, the PDEB1 isoform, has gained attention as a 
potential drug target for Human African Trypanosomiasis (HAT). Phosphodiesterases cleave phosphodiester 
bonds in cyclic nucleotides like cyclic AMP (cAMP), which is an important second messenger involved in 
regulation of signal transduction. An overview about cAMP signalling in trypanosomatids and differences 
between parasitic and human pathways that can be exploited for drug discovery can be found in the review 
by Tagoe et al. (2015). Herein, we focus on the recent efforts made to develop inhibitors of TbPDEB1.
Since inhibitors of human PDEs, like cilomilast, piclamilast, sildenafil and tadalafil were known, 
design efforts were often focused on repurposing these drugs and developing analogs thereof (Amata et 
al. 2014, Ochiana et al. 2012, Wang et al. 2012, Woodring et al. 2013), but with rather limited success. 
For example, Amata et al. (2014) found that cilomilast 143 (Figure 52) had an IC50 of 16.4 μM against 
TbPDEB1 and the best derivative 144 (Figure 52) resulted in an IC50 of 0.95 μM. However, the EC50 of 
144 in a cellular assay against T. brucei was still only modest (26 μM vs. cilomilast 143 EC50 > 50 μM).
A virtual screening of the ZINC database was carried out by Jansen et al. (2013) to broaden the 
chemical space of the potential TbPDEB1 inhibitors. Molecular docking in conjunction with a score based 
on receptor-compound interaction fingerprints was used to filter suitable compounds. This way, six novel 
inhibitors of TbPDEB1 with IC50 values between 10 and 80 μM were identified.
In another study, Orrling et al. (2012) used homology modeling and docking studies to exploit a 
parasite-specific subpocket, the so-called P-pocket of TbPDEB1 (Figure 53), for the design of the improved 
catechol pyrazolinone-based inhibitors. The most potent inhibitor 145 (Figure 54) achieved an IC50 of 
49 nM against TbPDEB1 and was able to inhibit parasite trypomastigote proliferation in in vitro studies: 
T. brucei rhodesiense with IC50 of 60 nM, T. brucei brucei with IC50 of 520 nM and T. cruzi with IC50 of 
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Figure 53. Compound 147 binding to TbPDEB1 (see also Figure 52, based on PDB-ID 5l8c) and targeting the parasite 
PDE-specific P-pocket. On the left, the protein is shown as a semi-transparent surface with the ligand in black sticks and 
the location of the P-pocket marked. On the right side, the protein is shown in the same orientation as cartoon and only the 
P-pocket residues are shown as a surface with residues labeled according to Blaazer et al. (2018).
Figure 54. Structure of the P-pocket targeting TbPDEB1 inhibitor 145.
Figure 52. Structures of the human PDE inhibitor cilomilast 143 and its derivative 144 optimized for TbPDEB1 targeting.
7.6 μM. However, compound 145 was an even more potent inhibitor of human PDE isoforms. Thus, this 
study highlights the potential of PDE inhibitors against trypanosomal infections, but also indicates that 
further optimization of the selectivity for the TbPDEB1 target is required.
The P-pocket of TbPDEB1 has been recently further exploited by Blaazer et al. (2018) in 
their development of selective 4a,5,8,8a-tetrahydrophthalazinone-based inhibitors. Guided by the 
crystallographic analysis of non-specific TbPDEB1 inhibitors and the analysis of flexibility patterns of 
a TbPDEB1-inhibitor complex observed by MD simulations, several compounds specifically targeting 
the P-pocket were developed. 146 and 147 (Figure 55) were overall the best, both showing Ki of 100 nM 
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against TbPDEB1, 10- and 19-fold selectivity for the parasitic over the human enzyme, and had IC50s of 
5.5 μM and 6.7 μM, respectively, when tested against T. brucei.
Cysteine proteases
Two cysteine proteases structurally related to human cathepsin, L: cruzain of T. cruzi and rhodesain of 
T. brucei rhodesiense, have been subject to many drug development efforts, including many 
computational and mechanistic studies in the past years, which we review below. More details on inhibitor 
design against cysteine proteases in Trypanosoma can be found in the recent review by Ferreira and 
Andricopulo (2017).
Cruzain: Since cruzain is a protease, many inhibitors designed were based on peptides and typically 
bind covalently (see Figure 56). Database screening strategies led to non-peptide inhibitors of cruzain. 
Ferreira et al. (2010) illustrated for cruzain inhibitors how the combination of VS, HTS and prioritization 
of molecular scaffolds can largely avoid false-positives. Wiggers et al. (2013) identified non-covalent 
cruzain inhibitors from the ZINC database. Further, Palos et al. (2017) performed VS of FDA-approved 
drugs against cruzain and confirmed the trypanocidal potential of four putative inhibitors in vitro and in 
vivo, which may thus represent starting scaffolds for further drug development. 
Figure 55. Interaction diagrams of the two P-pocket-targeting TbPDEB1 inhibitors, 146 and 147 (cf. Figure 53). The diagrams 
are based on the crystallographic complexes with PDB-ID 5g2b and 5l8c (Blaazer et al. 2018), respectively. Pocket-lining 
residues and the pocket shape are shown. Gray dotted lines indicate π-π interactions and black arrows show hydrogen-bonding 
interactions.
Figure 56. Example of a dipeptidyl nitrile ligand 148 covalently attached to the cysteine protease cruzain (see also 
Figure 57, based on PDB-ID 4qh6; Avelar et al. 2015). On the left, the protein is shown as a semi-transparent surface with 
the ligand in black sticks. On the right, the protein is shown in cartoon representation, rotated by about 90° and the site of the 
covalent attachment, Cys25 is labeled.
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Crystallography was also used for exploring compound binding modes, MoA, and for obtaining 
SAR. In the aforementioned VS study, Wiggers et al. (2013) used a molecular simplification approach to 
obtain a SAR for one of the compounds and found that the 2-acetamidothiophene-3-carboxamide scaffold 
was the critical component for the interactions with cruzain. Then, they confirmed the binding mode of 
this scaffold by crystallographic data, thus validating a potential new non-covalent, non-peptidic cruzain-
binding scaffold. Avelar et al. (2015) characterized dipeptidyl nitriles as inhibitors of cruzain by extensive 
SAR studies and determining a crystallographic complex with compound 148 (Figures 56 and 57). Jones 
et al. (2015) synthesized and crystallized oxyguanidine analogs of existing cysteine protease inhibitors 
Figure 57. Interaction diagrams of cruzain inhibitors: the covalent dipeptidyl nitrile 148 (left, see also Figure 56; Avelar et al. 
2015) and non-covalent oxyguanidine inhibitors 149 and 150 (middle and right; Jones et al. 2015). The diagrams are based on 
the crystallographic complexes with PDB-ID 4qh6, 4pi3 and 4xui, respectively. Pocket-lining residues and the pocket shape 
are shown. Gray dotted lines indicate π-π interactions, black arrows show hydrogen-bonding interactions, and a black line 
ended with circles marks a covalent bond between ligand and protein.
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and were able to show that one of the compounds displays covalent (149, Figure 57) and the other non-
covalent inhibition (150, Figure 57). 
A variety of computational chemistry methods has been used to study cruzain interactions with 
inhibitors, to better understand their MoA, and to design new compounds. Hologram quantitative structure-
activity relationship, comparative molecular field analysis and comparative molecular similarity index 
analysis methods combined with docking simulations have been applied to a series of benzimidazole-
based cruzain inhibitors by Pauli et al. (2017) to predict binding modes and activities. Silva et al. (2017) 
used docking studies and QSAR methods to study nitrile-containing cruzain inhibitors and predict 
their activities, leading to the proposal of new potential inhibitors. de Souza et al. (2017) used 2D- and 
3D-QSAR methods to explore the interactions of oxadiazole-based compounds with different cruzain 
subsites. Elizondo-Jimenez et al. (2017) synthesized benzenesulfonyl and N-propionyl benzenesulfonyl 
hydrazone derivatives, evaluated their anti-T. cruzi activity and used docking studies to propose covalent 
binding to cruzain as the compounds’ MoA. Silva-Júnior et al. (2016) synthesized several trypanocidal 
thiophen-2-iminothiazolidines and used molecular docking to demonstrate that the most active compound 
likely interacts simultaneously with two subsites of cruzain.
To gain more insight into cruzain dynamics and its interactions with inhibitors, MD simulations have 
been applied together with other molecular modelling techniques. Durrant et al. (2010) used sequence 
analysis and MD simulations to explore additional binding sites in cruzain. Hoelz et al. (2016) studied free 
and liganded cruzain dynamics at acidic pH, which corresponds to its environment in the cell. Very recently, 
Cianni et al. (2018) also used MD simulations to study the binding mode of reversible covalent inhibitors 
to the less frequently studied specific subsite S3 of cruzain. Finally, Martins et al. (2018) demonstrated a 
comprehensive computational approach including docking, MD, ab initio and MM/PBSA calculations for 
binding mode prediction and estimation of the contributions of specific amino acids to binding. Finally, 
more mechanistic approaches have been carried out, for example by Arafet et al. (2015, 2017) who 
studied the MoA of peptidyl-epoxyketone- or peptidyl-halomethyl-ketone-based cruzain inhibitors with a 
QM/MM method.
Rhodesain: For rhodesain, several SBDD efforts were inspired by its structural similarity to human 
cathepsin. Triazine nitrile-based compounds were studied against rhodesain and extensive SAR analyses 
were performed to explore the binding preferences of the different subsites, supported by a crystallographic 
complex of the synthesized compounds with the structurally related human cathepsin L enzyme (Ehmke 
et al. 2013). Schirmeister et al. (2017) aimed at repurposing human cathepsin-targeting dipeptide nitriles 
for rhodesain and used covalent docking to support the development of a SAR. Later, Giroud et al. (2018) 
optimized a set of macrocyclic lactams, developed as human cathepsin L inhibitors, to target T. brucei 
rhodesain and elucidated their binding modes by crystallographic studies. The initial compound 151 
(Figure 58) had a Ki of 11 nM against rhodesain, but also a Ki of 10 nM against human cathepsin L. One 
of the optimized, designed pyrazole derivatives 152 (Figure 58) was found to be about 11 times more 
effective as an inhibitor of rhodesain than human cathepsin L (Ki rhodesain 5.2 nM; Ki human cathepsin 
L 55.7 nM) and to be a potent inhibitor of T. b. rhodesiense with an IC50 of 0.6 nM. 
Trypanothione metabolism
The redox metabolism of parasites like T. brucei relies, in contrast to humans, on the dithiol trypanothione 
153 (N1,N8-bis(glutathionyl)spermidine; see Figure 59) being absent in humans and making enzymes 
involved in this pathway interesting as drug targets for trypanosomatidic diseases (Fairlamb and Cerami 
1992, Leroux and Krauth-Siegel 2016). One of the best studied and genetically validated targets is 
trypanothione reductase (TrypR; see Figure 59), which is responsible for reducing trypanothione disulfide 
(Fairlamb and Cerami 1992, Krieger et al. 2000). In humans, a similar reaction is performed by glutathione 
reductase, which, however, has an opposite net charge in the active site, facilitating the development of 
specific inhibitors (Faerman et al. 1996). 
Structure-based modelling provided insights into the TrypR pocket regions that could be targeted 
in drug design approaches. For example, Patterson et al. (2011) designed 3,4-dihydroquinazoline-based 
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inhibitors and solved several crystal structures of T. brucei TrypR. They observed conformational changes 
upon ligand binding, initiating the formation of a subpocket, which was exploited in further design and 
yielded compounds with improved TbTrypR and anti-trypanosomal activity: The initial hit compound 
154 (Figure 60) had an IC50 of 6.8 µM against TbTrypR and an EC50 against T. brucei of 40 µM, while 
the best designed compound 155 (Figure 60) yielded a TbTrypR IC50 of 0.23 µM and a T. brucei EC50 
of 0.73 µM.
In a later study, based on a series of peptide-based inhibitors, da Rocha Pita et al. (2012) developed 
receptor-dependent four-dimensional quantitative structure-activity relationship (RD-4D-QSAR) models 
(Pan et al. 2003) that allowed for identifying TrypR subsites that may be exploited in future inhibitor 
development. 
Figure 59. TrypR of T. brucei with trypanothione 153 bound at the interface between two chains (based on PDB-ID 2wow, 
chain A and B, ligand state A; Patterson et al. 2011). The protein is shown as a surface with trypanothione in black sticks.
Figure 58. Interaction diagrams of a macrolactam inhibitor of rhodesain 151 (left) and structure of its derivative 152 (right). 
The interaction diagram is based on the crystallographic complex with PDB-ID 6ex8 (Giroud et al. 2018). Pocket-lining 
residues and the pocket shape are shown. Black arrows in the interaction diagram indicate hydrogen-bonding interactions.
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Figure 60. Interaction diagrams of two dihydroquinazoline-based inhibitors of TbTrypR, 154 and 155. The diagrams are based 
on the crystallographic complexes with PDB-ID 2wp5 and 2wpf (Patterson et al. 2011), respectively. Pocket-lining residues 
and the pocket shape are shown. Gray dotted lines indicate π-π interactions, gray arrows indicate halogen-bonding interactions.
Using a combined approach including mutation studies, docking simulations, and crystallography, 
Persch et al. (2014) developed analogs of 1-[1-(benzo[b]thien-2-yl)cyclohexyl]piperidine as inhibitors of 
T. brucei and T. cruzi TrypR, targeting the large substrate binding site (Figure 56). For example, compound 
156 (Figure 61) displayed Ki values of 4 ± 0.5 μM against TcTrypR and 12 ± 2 μM against TbTrypR, 
when assuming a competitive inhibition mechanism. The IC50 against T. cruzi was 19.0 μM and against 
T. brucei rhodesiense—3.5 μM, with SI of 8 for L6 cells. However, there was some evidence that TrypR 
might not be the only target of the tested compounds. In a follow-up project (De Gasparo et al. 2018), again 
with the help of crystallographic studies, the cyclohexylpyrrolidine inhibitors were further optimized by 
retaining fragments that bind to the hydrophobic substrate binding site and by increasing the polarity of 
solvent-exposed moieties to improve aqueous solubility.
On the other hand, structure-based techniques helped in identifying TrypR as a potential target for some 
compounds active at the parasite level. This was the case for propyl/isopropyl quinoxaline-7-carboxylate 
1,4-di-N-oxide-based compounds, active against T. cruzi, which were found to target TrypR by using 
docking simulations and enzymatic validation (Chaćon-Vargas et al. 2017). Arias et al. (2017) synthesized 
a set of nitrofuran derivatives, which demonstrated uncompetitive inhibition of TrypR in subsequent 
experiments. Docking studies indicated that the inhibitors may in fact be capable of binding to the enzyme-
substrate complex, thus explaining the observed behavior. Similar observations were previously made for 
mesoionic 1,3,4-thiadiazolium-2-aminide (Rodrigues et al. 2012), which was also found to dock to TrypR 
in the presence of the substrate molecule. Finally, natural products or natural product-derived compounds, 
such as alkaloids or neolignan derivatives were proposed as inhibitors of TcTrypR on the basis of in silico 
screening, docking studies, and 2D-QSAR analysis (Argüelles et al. 2016, Hartmann et al. 2017).
Other enzymes of the trypanothione pathway were also investigated as potential drug targets. A 
mathematical model of the T. cruzi trypanothione pathway was developed by Olin-Sandoval et al. (2012). 
The results demonstrated that a polypharmacology approach targeting γ-glutamylcysteine synthetase (γECS) 
and trypanothione synthetase (TrypS) as the enzymes that exert the highest control on the pathway fluxes 
may be more promising than targeting TrypR. TrypR was found to have less metabolic control and thus 
requires very high ligand binding affinities to shut the pathway down. Further, by the same approach, 
tryparedoxin was identified as a suitable potential drug target, since it shows low catalytic efficiency and 
exerts large metabolic control (González-Chávez et al. 2015).
In line with the above findings, Benı́tez et al. (2016) focused on identifying TrypS inhibitors, using 
target-based screening of a compound library. Furthermore, Vázquez et al. (2017) discovered buthionine 
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sulfoximine as a dual inhibitor of γECS and TrypS, which was further confirmed by the docking and 
over-expression experiments. 
For a more detailed review on the system and currently known inhibitors of both TrypR and TrypS, 
the reader is referred to Leroux and Krauth-Siegel (2016).
Perspectives and limitations of target-based drug discovery approaches
Many of the examples presented herein demonstrate that it is not always trivial to translate good activities 
against a specific biomolecular target into anti-parasitic activity. However, target-guided approaches, like 
crystallography and computational docking studies, provide important guidelines for scaffold optimization 
and aid the development of SARs. Further, off-target effects can be minimized by the same techniques and 
comparative studies of, for instance, sequences, structures and molecular interaction fields. Computational 
studies of target dynamics provide further hints for desirable flexibility profiles of designed molecules. 
Moreover, mechanistic insights are gained by studying drug-target interactions. Target-based methods are 
under continuous development and offer great potential for finding suitable starting points for medicinal 
chemistry programs and the design of specific, selective compounds with a well-defined MoA. The choice 
of the target and its impact on the pathway to be inhibited is often a critical bottleneck and mathematical 
models of trypanosomal metabolic pathways may shed light on which enzymes have most control over 
pathway fluxes and thus may present the most promising targets. In summary, while many interesting 
compounds have been developed by target-based design strategies, there are limitations to the approach 
which are best overcome by combining target-guided approaches with screening of the compounds’ anti-
parasitic properties early on in the drug discovery process.
Figure 61. Interaction diagrams of piperidine-based inhibitor 156 in TbTrypR (left) and TcTrypR (right). The diagrams are 
based on the crystallographic complexes with PDB-ID 4nev and 4new (Persch et al. 2014), respectively. Pocket-lining residues 
and the pocket shape are shown. Gray dotted lines indicate π-π interactions.
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In vivo murine models in trypanosomatidic infections
Murine models, due to their small size, availability of tools for genetic manipulation and immunological 
studies, are at the forefront of animal use in science (Vandamme 2015). Notwithstanding, the use of 
animals in scientific research has always been a socially polarizing subject even with the implementation 
of the three Rs (Replacement, Reduction and Refinement) proposed more than 60 years ago (Russell 
and Burch 1959). For an animal model to be considered, there must be similarities related to disease 
etiology, pathophysiology, symptomatology and also response to therapeutic or prophylactic agents. In this 
sense, animal models have contributed decisively to the understanding of pathophysiological processes 
associated with infection and disease and have also been instrumental in pre-clinical vaccine and drug 
development.
For HAT, the animal models are well established and have predictive value for drug development 
(Field, Horn et al. 2017). These models were further solidified using highly susceptible BALB/c mice and 
bioluminescent parasites that enable longitudinal evaluation of drug performance (McLatchie, Burrell-
Saward et al. 2013, Burrell-Saward, Rodgers et al. 2015). Most models that exist are for stage 1 disease 
using the non-pathogenic T. b. brucei S427, although T. b. rhodesiense and to a lesser extent T. b. gambiense 
models also exist (Giroud, Ottones et al. 2009, Muchiri, Ndung’u et al. 2015, Field, Horn et al. 2017). 
Established models for stage 2 are also available using T. b. brucei GVR35 that induces a slow progressing 
infection in invasion of the central nervous system (Jennings, Urquhart et al. 1983, Burrell-Saward, Rodgers 
et al. 2015). For Chagas disease, the situation is quite different, as the translatability of the existing mice 
models to human disease is not linear as demonstrated by the posaconazole failure (Francisco, Lewis et 
al. 2015, Molina, Salvador et al. 2015). Many of the standardization issues that affect Leishmania mice 
models are also present in Chagas disease with completely different infection outcomes depending on the 
parasite strain, stage, inoculum and inoculation route affecting treatment susceptibility (Chatelain and Konar 
2015). Like in HAT, there are distinct animal models proposed for acute and chronic stages of the disease. 
The models for the acute stage are more common in drug development, which normally use high doses 
of parasites and are expected to be fatal after one month (Romanha, Castro et al. 2010). These models are 
typically used to demonstrate lack of efficacy of compounds and are considered not to be appropriate for 
lead development (Chatelain and Konar 2015). Chronic models also exist, requiring several months to be 
established with disease outcome being highly dependent on the strains used (Marinho, Bucci et al. 2004, 
Marinho, Nunez-Apaza et al. 2009). Therefore, these chronic models are considered time consuming and 
are expensive for drug development, requiring in-depth studies of the tissue tropism of the used strains 
(Chatelain and Konar 2015). A known technical limitation of the Chagas models was, for a long time, 
the detection of infection. This was problematic as these parasites are often absent from blood, requiring 
extensive examination of distinct tissues (Field, Horn et al. 2017). Nonetheless, this difficulty has been 
somewhat minimized with the use of bioluminescent parasites that, in conjunction with immunosuppressive 
treatments with cyclophosphamide, enable a better assessment of cure (Lewis, Francisco et al. 2015). 
Consequently, there is the notion that the existing mice models for Chagas disease have a limited predictive 
value for drug development, raising the need to improve the available mice models for Chagas (Chatelain 
and Konar 2015, Field, Horn et al. 2017).
Hamsters can be infected with several Trypanosoma sp and this species has been considered the most 
satisfactory and economic animal for maintenance of T. b. gambiense infection for experimental studies in 
laboratories (Lee and Pan 1980). However, as a rule, the use of hamsters as experimental models for HAT 
has been considerably less relevant compared to mice models (Pink et al. 2005). In the case of T. cruzi 
infections, hamster is considered a valuable model for Chagas disease studies in both acute and chronic 
phases of the infection (Ramirez et al. 1994), since they reproduce a range of different outcomes of the 
disease in humans (Bilate et al. 2008).
Ultimately, no perfect animal models exist but they have been essential to advance our knowledge 
of pathogenic mechanisms involved in these diseases and also to develop successful control approaches 
through vaccine and drug development (Pasquali 2018). 
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conclusion and Perspectives
In the present chapter, we have highlighted key medicinal chemistry approaches to identifying and assessing 
new hits and optimizing leads for tackling Chagas disease and HAT. The drug discovery approaches to the 
identification of new drugs for Chagas disease and HAT take advantage of the scope for collaborative work 
by different stakeholders, including academic research scientists, national and international organizations 
and governmental initiatives as well as private research centers and pharmaceutical companies. More 
financial support for the early stages of research and development is needed. Unfortunately, many research 
programs start and develop early hits and leads but then fall prematurely into the “valley of death” of 
unused early and late candidate compounds. A major effort devoted to further developing the most valuable 
compounds identified should be a core part of future research programs.
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